Janssen: New Clinical and Real-World Data Support Use of DARZALEX? (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma

Investigational daratumumab quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients with multiple myeloma in randomised Phase 2 GRIFFIN study1 Real-world evidence

Related Keywords

United States ,American ,Noah Reymond ,Edmond Chan Mbch ,Jacob Laubach ,Jessica Moore ,Imran Khan ,American Society Of Clinical Oncology ,Janssen Biotech Inc ,American Society Of Hematology Annual Meeting ,Jerome Lipper Multiple Myeloma Center ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,American Society Of Hematology ,Janssen Scientific Affairs ,Dana Farber Cancer Institute ,American Cancer Society ,None Of The Janssen Pharmaceutical Companies ,European Commission ,Flatiron Health ,Exchange Commission ,Companies Of Johnson ,European Commission Grants Marketing Authorisation ,European Medicines Agency ,Johnson ,American Society ,Edmond Chan ,Area Lead Haematology ,Clinical Director ,Medical Affairs ,New England Journal ,Real World Data ,Janssen Biotech ,Product Characteristics ,Pharmaceutical Companies ,Cardiovascular Metabolism ,Infectious Diseases Vaccines ,Janssen Cilag Limited ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Annual Report ,Note Regarding Forward Looking ,Quarterly Report ,Plus Lenalidomide ,Updated Analysis ,Oral Presentation To Be Presented ,Hematology Annual ,First Line Use ,Dexamethasone Confers Survival Benefit Compared ,Second Line Use ,Daratumumab Based Regimens ,Transplant Ineligible Patients ,Multiple Myeloma ,Different Clinical ,Real World Patient Characteristics ,Dexamethasone As First Line ,Newly Diagnosed Multiple Myeloma ,Impaired Renal Function ,Study Based ,Lenalidomide Starting ,Comparing Daratumumab ,Versus Lenalidomide ,Subjects With Newly Diagnosed Multiple Myeloma ,Dexamethasone With Lenalidomide ,Commission Grants Marketing Authorisation ,Subcutaneous Formulation ,Dexamethasone Versus Bortezomib ,Patients With Previously Treated Multiple Myeloma ,Three Year Follow Up ,Lymphoma Myeloma ,Today Population Factsheets ,Janssen ,Linical ,Meal ,World ,Data ,Support ,Darzalex ,Daratumumab ,Patients ,Ewly ,Diagnosed ,Multiple ,Myeloma ,